<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7121811/results/search/test_trace/results.xml">
  <result pre="nanoscale materials/formulations with the potential to be used for the" exact="treatment" post="or inhibition of the spread of viral diseases caused"/>
  <result pre="of new safe and potent antivirals with activity against viral" exact="infection" post="at multiple points in the viral life cycle remains"/>
  <result pre="nanoparticle (NP) systems as vaccines estimated for the prevention or" exact="treatment" post="of infectious diseases, chronic diseases, cancer, and addiction were"/>
  <result pre="interact with viral glycoproteins, shield virus surfaces, and efficiently block" exact="infection" post="and were found to act as robust inhibitors for"/>
  <result pre="surfactant proteins A and D mediated protection against influenza A" exact="infection" post="in vitro (McKenzie et al. 2015). Substitution of sulfate"/>
  <result pre="is a lentivirus (a subgroup of retrovirus) that causes HIV" exact="infection" post="and over time acquired immunodeficiency syndrome (AIDS). HIV is"/>
  <result pre="condom as a new approach to inhibit HIV- and HSV-transmitted" exact="infection" post="was proposed by Fayaz et al. (2012). At treatment"/>
  <result pre="HSV-transmitted infection was proposed by Fayaz et al. (2012). At" exact="treatment" post="of HIV-1 infected cells with curcumin-stabilized AgNPs of 45"/>
  <result pre="HIV envelope glycoprotein gp120 and inhibit in vitro the HIV" exact="infection" post="of T cells at nanomolar concentrations were reported by"/>
  <result pre="and dose-dependent reduction against both cell-free and cell-associated HIV-1 BaL" exact="infection" post="in vitro was estimated mainly for ARV NPs combinations"/>
  <result pre="formulation could ensure once-biweekly dosing to prevent or treat HIV" exact="infection" post="(Mandal et al. 2017b). PLGA-EVG NPs (~47 nm; zeta"/>
  <result pre="and at low doses it could be used for antiviral" exact="treatment" post="resulting in reduction of drug resistance and other side"/>
  <result pre="a hybrid system combining liposomes and magneto-plasmonic NPs, enabled the" exact="treatment" post="in the brain microenvironment that is inaccessible to most"/>
  <result pre="receptor demonstrated low neurotoxicity and high antiviral activity against HIV" exact="infection" post="in the brain (Gerson et al. 2014). A cell"/>
  <result pre="for 5 weeks and could be proposed for a long-acting" exact="treatment" post="with the potential to target residual virus in tissues"/>
  <result pre="family of viruses. Type A influenza is a contagious viral" exact="infection" post="that can have life-threatening complications if left untreated. An"/>
  <result pre="(Kuchipudi and Niessly 2018). Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus" exact="infection" post="by AgNPs in vitro and in vivo was reported"/>
  <result pre="HA damage, 20% of neuraminidase activities, and reduction of the" exact="infection" post="caused by the virus in Madin-Darby Canine Kidney (MDCK)"/>
  <result pre="et al. (2016) proposed a new modality to inhibit viral" exact="infection" post="by fabricating DNA-conjugated AuNPs networks on cell membranes as"/>
  <result pre="with sialic acid-functionalized AuNPs is expected to competitively inhibit viral" exact="infection" post="(Papp et al. 2010). Intranasal immunizations with a mixture"/>
  <result pre="hydroxyl radicals, suggesting that they could be applied in filters," exact="face masks," post="protective clothing, and kitchen cloths as a material suitable"/>
  <result pre="ribavirin (RBV), a broad-spectrum antiviral drug, protected cells during H1N1" exact="infection" post="in vitro, while in in vivo experiments they prevented"/>
  <result pre="this nanoformulation is a promising system for controlling influenza virus" exact="infection" post="(Jamali et al. 2018). Figueira et al. (2018) modified"/>
  <result pre="the formulation resulted in broadly protective immunity against a lethal" exact="infection" post="with heterosubtypic influenza virus, immune protection being mediated by"/>
  <result pre="adjuvant. These NPs also confer complete protection against a lethal" exact="infection" post="of homo-subtypic H1N1 and hetero-subtypic H9N2 virus and could"/>
  <result pre="the most important primary pathogens of swine respiratory disease and" exact="infection" post="is primarily with H1N1, H1N2, and H3N2 influenza A"/>
  <result pre="AIV subtype H7N3, when incubated with the virus prior to" exact="infection" post="as well as introduced to cells after infection, whereby"/>
  <result pre="and IgA) at the site of inoculation and in challenge" exact="tests" post="in BALI/c mice with several viruses (H5N1, H1N1, H5N2,"/>
  <result pre="in rhesus macaques (Liang et al. 2017). The results of" exact="hemagglutination" post="inhibition and micro-neutralization assays showed that lipid NP-formulated modified"/>
  <result pre="al. 2013). Curcumin-modified AgNPs showed strong inhibitory activity against RSV" exact="infection" post="resulting in a reduction of viral titers about two"/>
  <result pre="and was able to prevent the host cells from RSV" exact="infection" post="by directly inactivating the virus and inhibiting the viral"/>
  <result pre="causes genital herpes and these viruses can establish lifelong latent" exact="infection" post="within peripheral nervous system (Dai and Zhou 2018). Size-dependent"/>
  <result pre="(2013). AgNPs applied at nontoxic concentrations administered prior to viral" exact="infection" post="or soon after initial virus exposure were capable to"/>
  <result pre="33, and 46 nm showed antiviral activity and reduced both" exact="infection" post="and inflammatory reaction in the mouse model of HSV-2"/>
  <result pre="in the mouse model of HSV-2 infection, when used at" exact="infection" post="or for a postinfection treatment (Orlowski et al. 2014),"/>
  <result pre="HSV-2 infection, when used at infection or for a postinfection" exact="treatment" post="(Orlowski et al. 2014), and antiviral activity of such"/>
  <result pre="al. 2018a). Multifunctional tannic acid/AgNPs-based mucoadhesive hydrogel for effective vaginal" exact="treatment" post="of HSV-2 genital infection was also reported (Szymanska et"/>
  <result pre="acid/AgNPs-based mucoadhesive hydrogel for effective vaginal treatment of HSV-2 genital" exact="infection" post="was also reported (Szymanska et al. 2018). Investigation of"/>
  <result pre="viral attachment, entry, and cell-to-cell spread, thereby preventing subsequent viral" exact="infection" post="in a multimodal manner (Baram-Pinto et al. 2010). However,"/>
  <result pre="enter into human corneal fibroblasts—a natural target cell for HSV-1" exact="infection" post="and exhibited pronouncedly enhanced anti-HSV-1 effect creating additional oxygen"/>
  <result pre="were found to be an effective suppressor of HSV-2 genital" exact="infection" post="in female BALB/c mice, suppressing also a reinfection, and"/>
  <result pre="2012). Acyclovir (ACV)-loaded glycosaminoglycan-modified mesoporous SiO2 NPs reduced the viral" exact="infection" post="with HSV and such NPs were able to simultaneously"/>
  <result pre="found to operate as effective viral inhibitor and inhibited HSV" exact="infection" post="at an early stage during entry but did not"/>
  <result pre="demonstrated excellent binding as well as efficient inhibition of the" exact="infection" post="with orthopoxvirus possessing a HS-dependent cell entry mechanism (Ziem"/>
  <result pre="2016). Carbon nanodots surface-functionalized with 4-aminophenylboronic acid hydrochloride prevented HSV-1" exact="infection" post="on Vero and A549 cells and showed EC50 of"/>
  <result pre="a promising system for the effective drug delivery in the" exact="treatment" post="of herpes infections (dos Santos et al. 2017). Cymbopogon"/>
  <result pre="to be used in topically delivering pentyl gallate in the" exact="treatment" post="of human herpes labialis infection affecting primarily the lip"/>
  <result pre="delivering pentyl gallate in the treatment of human herpes labialis" exact="infection" post="affecting primarily the lip (Kelmann et al. 2016). Enhanced"/>
  <result pre="and suitability of such formulation for topical application against HSV-1" exact="infection" post="(Sharma et al. 2017b). ACV entrapped in nanostructured lipid"/>
  <result pre="such vaccine could be successfully used in Herpes simplex keratitis" exact="treatment" post="(Tang et al. 2018). Biomimetic supramolecular hexagonal-shaped nanoassemblies composed"/>
  <result pre="Lee et al. (2012) proposed hyaluronic acid-AuNPs/interferon-α complex for targeted" exact="treatment" post="of HCV infection. Antiviral effect of AuNPs showing small"/>
  <result pre="replication was observed and they were found to stop HCV" exact="infection" post="both at the attachment and entry stages suggesting that"/>
  <result pre="stages suggesting that Cu2O NPs could be used in the" exact="treatment" post="of patients with chronic hepatitis C (Hang et al."/>
  <result pre="with baicalin and folic acid surface-modifications designed for the targeted" exact="treatment" post="of HBV-infected liver cancer primarily targeted lysosomes in HepG2215"/>
  <result pre="observed, suggesting that the nanoformulation could be used for long-term" exact="treatment" post="of chronic hepatitis B instead of the daily dose"/>
  <result pre="were found to be excellent HCV entry inhibitors preventing HCV" exact="infection" post="in the micromolar range (Khanal et al. 2015). Phenylboronic-acid-modified"/>
  <result pre="hemorrhagic fever and it is one of the most dangerous" exact="infection" post="diseases with mortality rates up to 90%. The EBOVs"/>
  <result pre="IgG and neutralizing antibody responses and 100% survival after EBOV" exact="infection" post="(Meyer et al. 2018). Adjuvant-free dendrimer NPs vaccine platform"/>
  <result pre="log10) (Thi et al. 2016). Similar results were received with" exact="treatment" post="of Ebola-virus-Makona-infected nonhuman primates following administration of siRNA encapsulated"/>
  <result pre="rates. The virus is transmitted from animals to humans by" exact="contact" post="with bats or monkeys, or their bodily secretions or"/>
  <result pre="(Thi et al. 2014) and protection against lethal Marburg virus" exact="infection" post="mediated by lipid encapsulated siRNA was also observed with"/>
  <result pre="virus-infected guinea pigs (Ursic-Bedoya et al. 2014). Blocking of the" exact="infection" post="of T-lymphocytes and human dendritic cells by Ebola virus"/>
  <result pre="humoral, cellular, and mucosal immune responses protecting animals from the" exact="infection" post="of highly virulent NDV and avian infectious bronchitis virus"/>
  <result pre="of biomimetic nanodecoy (ND) that traps ZIKV and inhibits ZIKV" exact="infection" post="was suggested by Rao et al. (2019). The ND,"/>
  <result pre="of Japanese encephalitis virus (JEV) at noncytotoxic concentrations and blocked" exact="infection" post="with DENV and influenza A virus and also reduced"/>
  <result pre="virus and also reduced the lethality of JEV and DENV" exact="infection" post="in mouse challenge models (Liang et al. 2014). Efficiency"/>
  <result pre="Alphaherpesvirinae subfamily, and the etiological agent of Aujeszky’s disease. PRV" exact="infection" post="progresses from acute infection of the respiratory epithelium to"/>
  <result pre="etiological agent of Aujeszky’s disease. PRV infection progresses from acute" exact="infection" post="of the respiratory epithelium to latent infection in the"/>
  <result pre="progresses from acute infection of the respiratory epithelium to latent" exact="infection" post="in the peripheral nervous system, whereby sporadic reactivation from"/>
  <result pre="a RNA virus, porcine epidemic diarrhea virus (PEDV), suppressed the" exact="infection" post="of these viruses for a 2 log reduction, and"/>
  <result pre="by macropinocytosis-dependent mechanism, which resulted in inhibition of Vaccinia virus" exact="infection" post="(Trefry and Wooley 2013). Broglie et al. (2015) tested"/>
  <result pre="that virucidal efficacy significantly increased with increasing NPs concentration and/or" exact="contact" post="time of virus-like particles with NPs. CuI NPs demonstrated"/>
  <result pre="virus by more than 90% at the early stages of" exact="infection" post="such as attachment and penetration but not after penetration"/>
  <result pre="(BRSV) encapsulated in polyanhydride NPs and tested it against BRSV" exact="infection" post="using a neonatal calf model. They observed reduced pathology"/>
  <result pre="as a model of coronavirus and pronounced reduction of the" exact="infection" post="of PEDV by about three orders of magnitude at"/>
  <result pre="multivalent gold nanoparticlesSmall201061044105010.1002/smll.20090238420394070 Baram-PintoDShuklaSPerkasNGedankenASaridRInhibition of herpes simplex virus type 1" exact="infection" post="by silver nanoparticles capped with mercaptoethane sulfonateBioconjug Chem2009201497150210.1021/bc900215b21141805 BarrasAPagneuxQSaneFWangQBoukherroubRHoberDSzuneritsSHigh"/>
  <result pre="issues2015AmsterdamElsevier DonalisioMLeoneFCivraASpagnoloROzerOLemboDCavalliRAcyclovir-loaded chitosan nanospheres from nano-emulsion templating for the topical" exact="treatment" post="of herpesviruses infectionsPharmaceutics2018104610.3390/pharmaceutics100200466027529 dos SantosTCRescignanoNBoffLReginattoFHSimoesCMOde CamposAMMijangosCIn vitro antiherpes effect"/>
  <result pre="GersonTMakarovESenanayakeTHGorantlaSPoluektovaLYVinogradovSVNano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV" exact="infection" post="in the brainNanomedicine20141017718510.1016/j.nano.2013.06.01223845925 GongYuqingChowdhuryPallabitaMiddeNarasimha M.RahmanMohammad A.YallapuMurali M.KumarSantoshNovel elvitegravir nanoformulation"/>
  <result pre="Photobiol B201717413314310.1016/j.jphotobiol.2017.07.02628772238 JackmanJALeeJChoNJNanomedicine for infectious disease applications: innovation towards broad-spectrum" exact="treatment" post="of viral infectionsSmall2016121133113910.1002/smll.20150085426551316 JamaliAMottaghitalabFAbdoliADinarvandMEsmailieAKheiriMTAtyabiFInhibiting influenza virus replication and inducing"/>
  <result pre="replicationInt J Nanomedicine20151090392125673987 KelmannRGColomboMLopesSCDNunesRJPistoreMAgnolDDRigottoCSilvaITRomanSSTeixeiraHFOliveira SimõesCMKoesterLSPentyl gallate nanoemulsions as potential topical" exact="treatment" post="of herpes labialisJ Pharm Sci20161052194220310.1016/j.xphs.2016.04.02827290627 KhanalMBarrasAVausselinTFeneantLBoukherroubRSiriwardenaADubuissonJSzuneritsSBoronic acid-modified lipid nanocapsules:"/>
  <result pre="Rev Nanomed Nanobiotechnol2016855457810.1002/wnan.138326782096 LeeMYYangJAJungHSBeackSChoiJEHurWKooHKimKYoonSKHahnSKHyaluronic acid-gold nanoparticle/interferon α complex for targeted" exact="treatment" post="of hepatitis C virus infectionACS Nano201269522953110.1021/nn302538y23092111 LemboDSwaminathanSDonalisioMCivraAPasteroLAquilanoDVaviaPTrottaFCavalliREncapsulation of Acyclovir"/>
  <result pre="targeting dynamic membrane glycan receptorsLangmuir2018348415842110.1021/acs.langmuir.8b0160529958494 LinZFLiYHGongGFXiaYWangCBChenYHuaLZhongJYTangYLiuXMZhuBRestriction of H1N1 influenza virus" exact="infection" post="by selenium nanoparticles loaded with ribavirin via resisting caspase-3"/>
  <result pre="replicationAntivir Ther20081325326218505176 MandalSBelshanMHolecAZhouYDestacheCAn enhanced emtricitabine-loaded long-acting nanoformulation for prevention or" exact="treatment" post="of HIV infectionAntimicrob Agents Chemother201761e01475e0141610.1128/AAC.01475-1627821449 MandalSPrathipatiPKKangGBZhouYYuanZFanWJLiQSDestacheCJTenofovir alafenamide and and"/>
  <result pre="Sci20181071787179010.1016/j.xphs.2018.03.00529548975 McGillJLKellySMKumarPSpeckhartSHaughneySLHenningsonJNarasimhanBSaccoREEfficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus" exact="infection" post="in the neonatal calfSci Rep20188302110.1038/s41598-018-21292-229445124 McKenzieZKendallMMackayRMTetleyTDMorganCGriffithsMClarkHWMadsenJNanoparticles modulate surfactant protein"/>
  <result pre="surfactant protein A and D mediated protection against influenza A" exact="infection" post="in vitroPhilos Trans R Soc Lond B Biol Sci20153702014004910.1098/rstb.2014.004925533100"/>
  <result pre="scavengers of hazardous virusesJ Nanopart Res201416243010.1007/s11051-014-2430-2 PappISiebenCLudwigKRoskampMBoettcherCSchlechtSHerrmannAHaagRInhibition of influenza virus" exact="infection" post="by multivalent sialic-acid-functionalized gold nanoparticlesSmall201062900290610.1002/smll.20100134921104827 ParboosingRMaguireGEMGovenderPKrugerHGNanotechnology and the treatment"/>
  <result pre="virus infection by multivalent sialic-acid-functionalized gold nanoparticlesSmall201062900290610.1002/smll.20100134921104827 ParboosingRMaguireGEMGovenderPKrugerHGNanotechnology and the" exact="treatment" post="of HIV infectionViruses2012448852010.3390/v404048822590683 ParkSJKoYSLeeSJLeeCWooKKoGInactivation of influenza A virus via"/>
  <result pre="Biol201532303910.1016/j.jtemb.2015.05.00526302909 RaoLWangWBMengQFTianMFCaiBWangYCLiAXZanMHXiaoFBuLLLiGLiALiuYGuoSSZhaoXZWangTHLiuWWuJA biomimetic nanodecoy traps Zika virus to prevent viral" exact="infection" post="and fetal microcephaly developmentNano Lett2019192215222210.1021/acs.nanolett.8b0391330543300 RenganathanSAroulmojiVShanmugamGDevarajadGRaoKVRajendarVParkSHSilver nanoparticle synthesis from"/>
  <result pre="developmentNano Lett2019192215222210.1021/acs.nanolett.8b0391330543300 RenganathanSAroulmojiVShanmugamGDevarajadGRaoKVRajendarVParkSHSilver nanoparticle synthesis from carica papaya and virtual" exact="screening" post="for anti-dengue activity using molecular dockingMater Res Express2019603502810.1088/2053-1591/aaf6fb Ribeiro-VianaRSanchez-NavarroMLuczkowiakJKoeppeJRDelgadoRRojoJDavisBGVirus-like"/>
  <result pre="long-acting nanoformulated dolutegravirNat Commun2018944310.1038/s41467-018-02885-x29402886 SinghLKrugerHGMaguireGEMGovenderTParboosingRThe role of nanotechnology in the" exact="treatment" post="of viral infectionsTher Adv Infect Dis2017410513128748089 SinghSMAlkieTNAbdelazizKTHodginsDCNovyANagyESharifSCharacterization of immune"/>
  <result pre="chickensVaccine2016344807481310.1016/j.vaccine.2016.08.00927543454 SmithGLiuYFlyerDMassareMJZhouBPatelNEllingsworthLLewisMCummingsJFGlennGNovel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces" exact="hemagglutination" post="inhibition, neutralizing, and protective responses in ferrets against homologous"/>
  <result pre="infectionsMolecules201520140511140810.3390/molecules20081405126247927 SzymanskaEOrlowskiPWinnickaKTomaszewskaEBaskaPCelichowskiGGrobelnyJBasaAKrzyzowskaMMultifunctional tannic acid/silver nanoparticle-based mucoadhesive hydrogel for improved local" exact="treatment" post="of HSV infection: in vitro and in vivo studiesInt"/>
  <result pre="Med Sci2014761277128010.1292/jvms.14-015824871643 ThiEPLeeACHGeisbertJBUrsic-BedoyaRAgansKNRobbinsMDeerDJFentonKAKondratowiczASMacLachlanIGeisbertTWMireCERescue of non-human primates from advanced Sudan ebolavirus" exact="infection" post="with lipid encapsulated siRNANat Microbiol201611614210.1038/nmicrobiol.2016.14227670117 ThiEPMireCELeeACHGeisbertJBZhouJZAgansKNSneadNMDeerDJBarnardTRFentonKAMacLachlanIGeisbertTWLipid nanoparticle siRNA treatment"/>
  <result pre="ebolavirus infection with lipid encapsulated siRNANat Microbiol201611614210.1038/nmicrobiol.2016.14227670117 ThiEPMireCELeeACHGeisbertJBZhouJZAgansKNSneadNMDeerDJBarnardTRFentonKAMacLachlanIGeisbertTWLipid nanoparticle siRNA" exact="treatment" post="of Ebola-virus-Makona-infected nonhuman primatesNature201552136236510.1038/nature1444225901685 ThiEPMireCEUrsic-BedoyaRGeisbertJBLeeACHAgansKNRobbinsMDeerDJFentonKAMacLachlanIGeisbertTWMarburg virus infection in nonhuman"/>
  <result pre="ThiEPMireCELeeACHGeisbertJBZhouJZAgansKNSneadNMDeerDJBarnardTRFentonKAMacLachlanIGeisbertTWLipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primatesNature201552136236510.1038/nature1444225901685 ThiEPMireCEUrsic-BedoyaRGeisbertJBLeeACHAgansKNRobbinsMDeerDJFentonKAMacLachlanIGeisbertTWMarburg virus" exact="infection" post="in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNASci Transl"/>
  <result pre="Ebola-virus-Makona-infected nonhuman primatesNature201552136236510.1038/nature1444225901685 ThiEPMireCEUrsic-BedoyaRGeisbertJBLeeACHAgansKNRobbinsMDeerDJFentonKAMacLachlanIGeisbertTWMarburg virus infection in nonhuman primates: therapeutic" exact="treatment" post="by lipid-encapsulated siRNASci Transl Med20146250ra11610.1126/scitranslmed.300970625143366 TiminASMuslimovARPetrovaAVLepikKVOkilovaMVVasinAVAfanasyevBVSukhorukovGBHybrid inorganic-organic capsules for"/>
  <result pre="image-guided and brain-targeted HIV treatmentNanoscale20181018419410.1039/C7NR07255D TrefryJCWooleyDPSilver nanoparticles inhibit vaccinia virus" exact="infection" post="by preventing viral entry through a macropinocytosis-dependent mechanismJ Biomed"/>
  <result pre="and cell-to-cell membrane fusionPLoS One20127e4814710.1371/journal.pone.004814723110193 Ursic-BedoyaRMireCERobbinsMGeisbertJBJudgeAMacLachlanIGeisbertTWProtection against lethal Marburg virus" exact="infection" post="mediated by lipid encapsulated small interfering RNAJ Infect Dis201420956257010.1093/infdis/jit46523990568"/>
  <result pre="in vitroJ Virol Methods201117813714210.1016/j.jviromet.2011.09.00321945220 XiangDXZhengYDuanWLiXJYinJJShigdarSO’ConnorMLMarappanMZhaoXJMiaoYQXiangBZhengCLLInhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus" exact="infection" post="by silver nanoparticles in vitro and in vivoInt J"/>
 </snippets>
</snippetsTree>
